^
    6d
    NY-ESO-1-specific T Cell Receptor (TCR) T Cell in Sarcoma (clinicaltrials.gov)
    P1, N=2, Completed, Sun Yat-sen University | Active, not recruiting --> Completed | N=20 --> 2 | Trial completion date: May 2024 --> Apr 2026
    Trial completion • Enrollment change • Trial completion date
    |
    CTAG1B (Cancer/testis antigen 1B)
    |
    cyclophosphamide • TAEST16001
    6d
    Phase II Study of TAEST16001 in Soft Tissue Sarcoma (clinicaltrials.gov)
    P2, N=8, Terminated, Sun Yat-sen University | N=70 --> 8 | Trial completion date: Sep 2024 --> Aug 2025 | Recruiting --> Terminated | Trial primary completion date: Sep 2024 --> Jul 2025; The study was terminated due to initiation of a new clinical trial with an updated study design.
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    CTAG1B (Cancer/testis antigen 1B)
    |
    TAEST16001
    24d
    The Landscape of Clinical Trials for TCR-T Cell Therapy. (PubMed, Am J Clin Oncol)
    NY-ESO-1 is the most prominent target, followed by MAGE-A4, KRAS, PRAME, HPV16 E6/E7, and HBV surface antigen, with letetresgene autoleucel and LioCyx-M004 being the most investigated TCR-T products. Collectively, TCR-T therapy is a promising field in tumor immunotherapy with continuous research investment and advancing clinical progress.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • CTAG1B (Cancer/testis antigen 1B) • MAGEA4 (Melanoma antigen family A, 4) • PRAME (Preferentially Expressed Antigen In Melanoma)
    |
    letetresgene autoleucel (GSK3377794) • LioCyx-M
    1m
    A2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer (clinicaltrials.gov)
    P1, N=20, Recruiting, University of Southern California | Suspended --> Recruiting | Trial completion date: Dec 2027 --> Dec 2028 | Trial primary completion date: Dec 2026 --> Dec 2027
    Enrollment open • Trial completion date • Trial primary completion date • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor) • CTAG1B (Cancer/testis antigen 1B)
    |
    HER-2 negative
    |
    cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • NY-ESO-1 TCR
    1m
    PANACEA: MT-601 Administered To Patients With Locally Advanced Unresectable or Metastatic Pancreatic Cancer (clinicaltrials.gov)
    P1, N=38, Not yet recruiting, Marker Therapeutics, Inc. | Trial completion date: Dec 2027 --> Sep 2028 | Trial primary completion date: Sep 2027 --> Jul 2028
    Trial completion date • Trial primary completion date
    2ms
    CRUKD/20/001: A Trial of ChAdOx1 and MVA Vaccines Against MAGE-A3 and NY-ESO-1 (clinicaltrials.gov)
    P1/2, N=15, Suspended, Cancer Research UK | Trial completion date: Mar 2029 --> Oct 2026
    Trial completion date • Checkpoint inhibition • First-in-human
    |
    PD-L1 (Programmed death ligand 1) • MAGEA3 (MAGE Family Member A3)
    |
    VTP-600
    3ms
    Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Untreated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoma (clinicaltrials.gov)
    P2, N=7, Active, not recruiting, USWM, LLC (dba US WorldMeds) | Trial completion date: Jul 2025 --> Jul 2026
    Trial completion date
    |
    CTAG1B (Cancer/testis antigen 1B)
    |
    cyclophosphamide • fludarabine IV • letetresgene autoleucel (GSK3377794)
    4ms
    Nanovaccines in Cancer Immunotherapy: Lymph Node-Targeted Strategies and Mechanistic Insights. (PubMed, Curr Pharm Des)
    Nanovaccine platforms can potentially overcome some constraints of conventional vaccines by enhancing lymph node targeting, antigen stability, and immunogenicity. Further research in this field could further advance targeted cancer immunotherapy.
    Journal
    |
    STING (stimulator of interferon response cGAMP interactor 1)
    |
    BNT111 • intismeran autogene (mRNA-4157)
    4ms
    Biomimetic and personalized nanovaccines in cancer immunotherapy: Design innovations, translational challenges, and future directions. (PubMed, J Adv Res)
    This review synthesizes recent advances in biomimetic and personalized nanovaccine design, highlighting clinical progress in lipid nanoparticle (LNP)-based vaccines such as BNT111 and mRNA-4157, emerging innate immune adjuvants including Toll-like receptor (TLR) and stimulator of interferon genes (STING) agonists, and rational combination strategies with immune checkpoint blockade. Key safety and quality consideration including immunotoxicity, off-target immune activation, and batch heterogeneity are critically evaluated alongside emerging engineering solutions. Finally, future directions integrating AI-guided neoantigen prediction, modular microfluidic manufacturing, and multi-omic biomarker frameworks are discussed to accelerate next generation cancer nanovaccine translation.
    Review • Journal • IO biomarker
    |
    STING (stimulator of interferon response cGAMP interactor 1)
    |
    BNT111 • intismeran autogene (mRNA-4157)
    5ms
    A2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer (clinicaltrials.gov)
    P1, N=20, Suspended, University of Southern California | Recruiting --> Suspended
    Trial suspension • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor) • CTAG1B (Cancer/testis antigen 1B)
    |
    HER-2 negative
    |
    cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • NY-ESO-1 TCR
    5ms
    Multi-center Study of TBI-1301 (INN: Mipetresgene Autoleucel; Mip-cel) in Patients With NY-ESO-1 Positive Synovial Sarcoma (clinicaltrials.gov)
    P3, N=5, Recruiting, Takara Bio Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    CTAG1B (Cancer/testis antigen 1B)
    |
    cyclophosphamide • fludarabine IV • mipetresgene autoleucel (TBI-1301)
    5ms
    BNT111-01: A Study to Investigate the Novel Agent BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Advanced Melanoma That Has Not Responded to Other Forms of Treatment (clinicaltrials.gov)
    P2, N=184, Completed, BioNTech SE | Active, not recruiting --> Completed
    Trial completion
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation • BRAF V600
    |
    Libtayo (cemiplimab-rwlc) • BNT111